Compare INOD & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INOD | MNKD |
|---|---|---|
| Founded | 1988 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 1993 | 2004 |
| Metric | INOD | MNKD |
|---|---|---|
| Price | $59.69 | $5.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $91.67 | $10.08 |
| AVG Volume (30 Days) | 1.1M | ★ 3.7M |
| Earning Date | 02-19-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.46 | 23.47 |
| EPS | ★ 1.01 | 0.10 |
| Revenue | $238,467,000.00 | ★ $313,787,000.00 |
| Revenue This Year | $48.85 | $21.40 |
| Revenue Next Year | $25.93 | $25.03 |
| P/E Ratio | $58.96 | ★ $55.78 |
| Revenue Growth | ★ 73.57 | 17.43 |
| 52 Week Low | $26.41 | $3.38 |
| 52 Week High | $93.85 | $6.51 |
| Indicator | INOD | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 50.77 | 46.52 |
| Support Level | $56.91 | $5.03 |
| Resistance Level | $65.65 | $6.05 |
| Average True Range (ATR) | 4.73 | 0.29 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 36.42 | 35.04 |
Innodata Inc is a data engineering company. It is helping companies deploy and integrate AI into their operations and products and providing AI-enabled industry platforms. The Company's operations are classified in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility. Key revenue is generated from DDS segment provides AI data preparation services, collecting or creating training data, annotating training data, and training AI algorithms for its customers, and AI model deployment and integration. It also provides a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.